The landscape of companies specifically focused on vulvar cancer might be limited compared to broader cancer research and treatment organizations. Vulvar cancer is a relatively rare type of cancer that affects the external female genitalia. However, various pharmaceutical and biotech companies, as well as research institutions, contribute to cancer research and the development of treatments that may be applicable to vulvar cancer.
Roche Holding AG Received FDA approval for their FoundationOne CDx assay, a comprehensive genomic profiling test, to guide personalized treatment decisions in vulvar cancer patients.
Guardant Health Expanded their liquid biopsy testing platform to include vulvar cancer, allowing for non-invasive tumor profiling and potentially improving treatment planning.
Myriad Genetics Developed a new genetic test panel specifically for vulvar cancer, offering a more comprehensive analysis of potential genetic risk factors and personalized treatment options.
Boston Scientific Corporation Launched a new vaginal dilator specifically designed for vulvar cancer survivors, addressing a critical need for post-treatment recovery and intimacy support.
Hologic Introduced their Aptima® HPV test with improved sensitivity for detecting HPV strains associated with vulvar cancer, contributing to earlier diagnosis and prevention efforts.
List of Vulvar Cancer Key Companies in the Market
Vulvar Cancer Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)